- Home
- WELL vs SNY Comparison
WELL vs SNY Comparison
Compare WELL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WELL | SNY |
|---|---|---|
| Founded | 1970 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7B | 104.5B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | WELL | SNY |
|---|---|---|
| Price | $235.56 | $42.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $224.38 | $58.00 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 1.40% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $10,838,034,000.00 | N/A |
| Revenue This Year | $28.56 | $3.49 |
| Revenue Next Year | $6.97 | $6.10 |
| P/E Ratio | $231.34 | ★ $6.14 |
| Revenue Growth | ★ 35.63 | N/A |
| 52 Week Low | $163.75 | $40.89 |
| 52 Week High | $255.20 | $52.68 |
Technical Indicators
Market Signals| Indicator | WELL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 35.88 |
| Support Level | $233.52 | $42.30 |
| Resistance Level | $241.07 | $45.22 |
| Average True Range (ATR) | 4.57 | 0.59 |
| MACD | -0.49 | -0.30 |
| Stochastic Oscillator | 21.64 | 1.89 |
Price Performance
Historical ComparisonAbout WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,800 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 900 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.